

**Name:** Leo Rasche, PD Dr. med.

**Work address:** Department of Internal Medicine II, University Hospital of Würzburg, Oberdürrbacher Strasse 6, 97080 Würzburg, phone +49 (0)931 201 43995, E-mail: Rasche\_L@ukw.de

**Current position**

2018-current: Group leader and senior physician, Department of Internal Medicine II, University of Würzburg Medical Center

**Previous professional and scientific appointments and milestones:**

2022 Habilitation in "Internal Medicine", Artur Pappenheim Award by the DGHO  
2016-2018: Postdoctoral Fellow, Stipend of the Deutsche Forschungsgemeinschaft (DFG), University of Arkansas for Medical Sciences, Little Rock, AR, USA  
2015 Board certification in Hematology, Oncology and Internal Medicine  
2009-2015 Resident, Department of Haematology, University Hospital of Würzburg, Germany  
2002-2008 Study of Medicine at University of Würzburg and University of Cape Town

**Top 5 peer reviewed publications with relevance to proposal (first or last author):**

- a. Leipold AM, Werner RA, Düll J, Jung P, John M, Stanojkovska E, Zhou X, Hornburger H, Ruckdeschel A, Dietrich O, Imdahl F, Krammer T, Knop S, Rosenwald A, Buck A, Sander LE, Einsele H, Kortüm KM, Saliba AE, **Rasche L**. Th17.1 cell driven sarcoidosis-like inflammation after anti-BCMA CAR T cells in multiple myeloma. **Leukemia** 2023 Jan 31;1-9
- b. **Rasche L**, Schinke C, Maura F, Bauer M, Ashby C., Deshpande S, Zangari M, Thanendrarajan S, Davies F., Walker B., Barlogie B., Landgren O, Morgan, G, Weinhold N. The Spatio-Temporal Evolution of Multiple Myeloma from Baseline to Relapse-Refractory States. **Nature Communications** 2022, *\*\*\*First study on the spatio-temporal evolution of MM in the bone marrow cavity*
- c. Truger MS, Duell J, Zhou X, Heimeshoff L, Ruckdeschel A, John M, Riedel A, Hüper S, Peter J, Walter W, Haertle L, Meggendorfer M, Topp MS, Rosenwald A, Da Via MC, Bolli N, Weinhold N, Einsele H, Haferlach C, Kortüm KM, **Rasche L**, Single- and double-hit events in genes encoding immune targets before and after T cell-engaging antibody therapy in MM, **Blood Advances**. 2021 Oct 12;5(19):3794-3798. *\*\*\*First report on biallelic BCMA loss as a mechanism of resistance to BCMAxCD3 bispecific antibodies*
- d. Da Vià MC, Dietrich O, Truger M, Arampatzi P, Duell J, Heidemeier A, Zhou X, Danhof S, Kraus S, Chatterjee M, Meggendorfer M, Twardziok S, Goebeler ME, Topp MS, Hudecek M, Prommersberger S, Hege K, Kaiser S, Fuhr V, Weinhold N, Rosenwald A, Erhard F, Haferlach C, Einsele H, Kortüm KM, Saliba AE, **Rasche L**, Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma. **Nature Medicine**. 2021 Feb 22. *\*\*\*First report on biallelic BCMA loss as a mechanism of resistance to anti-BCMA CAR T cells*
- e. **Rasche, L.\***, Angtuaco, E.\*, Alpe, T., Gershner, G., McDonald, J., Samant, R., Kumar, M., Van Hemert R., Epstein, J., Deshpande, S., Tytarenko, R., Yaccoby, S., Hillengass, J., Thanendarajan, S, Schinke, C., van Rhee, F, Zangari, M., Walker, B., Barlogie, B., Morgan, G.J., Davies, F.E., Weinhold, N. The presence of large focal lesions is a strong independent prognostic factor in Multiple Myeloma. **Blood**. 2018 May 21